The Socialist 23 January 2019

Corbyn: stand firm for a general election

Corbyn: stand firm for a general election

Nationalise big pharma: end this profit-driven NHS crisis

Duke's car crash: one law for them and another for us

Racist jobs discrimination same for 50 years - unions must fight for jobs for all

Wales is Europe's prisoner capital: capitalist cutters' crimes to blame

Them & Us

Cuban revolution at 60: defend the gains and fight for workers' democracy

Birmingham: hostile Labour council attacks striking workers

Mass strike wins historic step towards victory in Glasgow equal pay battle

John Lewis workers count the cost of the retail crisis

Unison union higher education conference: a missed opportunity to develop a fighting strategy

Bristol Deliveroo workers walk out

PCS union: re-elect Chris Baugh for assistant general secretary

Enfield North CLP backs no-cuts budget - now councillors must act

We need May Day greetings!

Leeds: don't let the far right divide us

Europe: school students strike against climate change

Poland: thousands mourn death of murdered mayor

International round-up

Theatre: Rouse, Ye Women to tell story of 1910 chainmakers' strike

Non-fiction: The Murder of Rosa Luxemburg "reveals the brutal lengths capitalists will go to protect their system"

PO Box 1398, Enfield EN1 9GT

020 8988 8777

editors@socialistparty.org.uk

Link to this page: https://secure.socialistparty.org.uk/issue/1026/28541

Search the site	Printable version

Home | The Socialist 23 January 2019 | Join the Socialist Party

Subscribe | Donate | Audio | PDF | ebook

NHS faces drug price hikes

Nationalise big pharma: end this profit-driven NHS crisis

Price controls not enough: we need democratic public ownership

Nationalise big pharma! (Click to enlarge)

Iain Dalton, Socialist Party national committee

Among all the other Brexit-related headlines, the latest crisis announced has been a projected shortage of generic, out-of-patent medicines.

The NHS was reportedly paying higher prices to suppliers of 80 products in December to shore up its supplies. According to Oxford University researchers, last month the total cost of these generic drugs was £37 million instead of the 'normal' £11.4 million.

But this isn't the first time in recent years there has been a spike in drug prices coinciding with projected shortages. In November 2017, 91 medicines were on the price concessions list (allowing companies to increase what they charge for them).

In reality, there are a number of factors that can lead to such shortages. These include increasing global demand and issues with the supply of raw materials. But linked with this are problems stemming from the nature of capitalist, profit-driven markets.

To boost profits, many companies cease to manufacture generic products in favour of more expensive and profitable patented brands. What's more, as the Healthcare Distribution Association has suggested, companies can stockpile medicines in a speculative fashion to make money as further shortages develop.

This rigging of the market in the interests of private profit, with scant regard for the healthcare needs of the population, is the dominant feature of the pharmaceutical industry.

According to a recent study, two thirds of patient groups appraising pharmaceuticals for regulatory body NICE receive funding from the very companies they are meant to be judging.

The government's own website to attract Big Pharma investment in the UK boasts an Effective Tax Rate of between 11% and 13%. 30% of all drugs used worldwide were developed in Britain.

Pharma giants

The UK's pharmaceutical industry is dominated by two giants, GlaxoSmithKline and AstraZeneca. These are the fifth and sixth largest drugs companies globally, both with profits over £2 billion in 2017.

Instead of subsidising their profits with tax breaks and guaranteeing large payments from the NHS, they should be nationalised under democratic workers' control and management.

This would allow production to be directly linked with what is needed in the NHS. It would free up funds that currently go to the vast profits of these companies for increased investment in research - helping to pave the way for fresh advances in the treatment of disease.

Drug production could be democratically planned by workers in the sector, the NHS and patient groups, and with the involvement of wider society.

Such measures, which would need to be taken as part of the socialist transformation of society, could inspire workers around the world who are struggling for decent health care and against the capitalist system.

Such a movement for socialist change would demand the multinational big pharma companies like Pfizer, Novartis, Merck, Sanofi and others are brought into public ownership - paving the way for a fully integrated, publicly owned and democratically run health service. In this way research data would no longer be hidden for commercial confidentially, but instead shared.

In this way we could begin to tackle global health problems in a coordinated fashion - to the benefit of all.

In this issue

What we think

Corbyn: stand firm for a general election